Search

Displaying results 2401 - 2410 of 4212 in total
  1. Drug

    Piperidione

    go.drugbank.com/drugs/DB13224
    Experimental

    Piperidione was cough medicine marketed by Roche under the trade name Sedulon.

  2. Drug

    Nocodazole

    go.drugbank.com/drugs/DB08313
    Experimental

    Nocodazole is an antineoplastic agent which exerts its effect by depolymerizing microtubules.

  3. Drug

    BCL-005

    go.drugbank.com/drugs/DB17242
    Experimental

    BCL-005 is a product formed by fused (hybrid) melanoma-dendritic cells.

  4. Drug

    Levobunolol

    go.drugbank.com/drugs/DB01210
    Approved

    A nonselective beta-adrenoceptor antagonist used in the treatment of glaucoma.

  5. Drug

    Strontium chloride Sr-89

    go.drugbank.com/drugs/DB09498
    Approved

    Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases. Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate can...

  6. Drug

    Pleconaril

    go.drugbank.com/drugs/DB05105
    Investigational

    It acts by inhibiting viral replication. The use of pleconaril has not gained approval by the U.S. … Pleconaril is an antiviral drug from _viral capsid inhibitor_ class, manufactured by _Schering-Plough_ and intended for the prevention of acute asthma exacerbations and common cold symptoms in asthmatic

  7. Drug

    G207

    go.drugbank.com/drugs/DB05827
    Investigational

    G207 is cancer-killing viruses, so-called oncolytic viruses, for the treatment of various forms of cancer developed by MediGene AG.

  8. Drug

    Denosumab

    go.drugbank.com/drugs/DB06643
    ApprovedInvestigational

    [A263066] Denosumab was approved by the FDA approved on June 2010 for the treatment of osteoporosis in postmenopausal women. … Two denosumab biosimilars—Wyost® (denosumab-bbdz) [L53063] and Jubbonti® (denosumab-bbdz)[L53058]—were approved by the FDA in March 2024 for all indications of the reference products Xgeva® and Prolia®

  9. Drug

    Influenza A virus A/Darwin/9/2021 IVR-228 (H3N2) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB16924
    ApprovedWithdrawn

    These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes

  10. Drug

    Influenza A Virus A/Sydney/5/2021 SAN-013 (H1N1) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB17751
    ApprovedWithdrawn

    These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes